Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2019 1
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Lysophosphatidic acid receptor LPAR6 supports the tumorigenicity of hepatocellular carcinoma.
Mazzocca A, Dituri F, De Santis F, Filannino A, Lopane C, Betz RC, Li YY, Mukaida N, Winter P, Tortorella C, Giannelli G, Sabbà C. Mazzocca A, et al. Cancer Res. 2015 Feb 1;75(3):532-43. doi: 10.1158/0008-5472.CAN-14-1607. Epub 2015 Jan 14. Cancer Res. 2015. PMID: 25589345
The aberrant processes driving hepatocellular carcinoma (HCC) are not fully understood. Lysophosphatidic acid receptors (LPAR) are commonly overexpressed in HCC, but their contributions to malignant development are not well established. ...We to …
The aberrant processes driving hepatocellular carcinoma (HCC) are not fully understood. Lysophosphatidic acid
Novel lysophosphatidic acid receptor 6 antagonists inhibit hepatocellular carcinoma growth through affecting mitochondrial function.
Gnocchi D, Kapoor S, Nitti P, Cavalluzzi MM, Lentini G, Denora N, Sabbà C, Mazzocca A. Gnocchi D, et al. J Mol Med (Berl). 2020 Feb;98(2):179-191. doi: 10.1007/s00109-019-01862-1. Epub 2019 Dec 20. J Mol Med (Berl). 2020. PMID: 31863151
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and the commonest liver cancer. ...Thus, searching for new effective and nontoxic molecules for HCC treatment is of paramount importance. We previously demonstrated that lysophosphatidi
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide and the commonest liver cancer. ...Thus, searchi